The tyrosine kinase inhibitors market size has grown strongly in recent years. It will grow from $58.03 billion in 2024 to $63.25 billion in 2025 at a compound annual growth rate (CAGR) of 9%. The growth in the historic period can be attributed to the discovery of tyrosine kinases, understanding of cancer signaling pathways, approval of imatinib (Gleevec), the clinical success of early TKIs, and investment in research and development.
The tyrosine kinase inhibitors market size is expected to see strong growth in the next few years. It will grow to $88.74 billion in 2029 at a compound annual growth rate (CAGR) of 8.8%. The growth in the forecast period can be attributed to growing healthcare investments, biomarker-driven therapies, drug delivery innovations, precision medicine paradigm, pediatric oncology focus. Major trends in the forecast period include resistance mitigation strategies, development of CNS-penetrant tkis, non-oncology applications, liquid biopsies for monitoring, health economic considerations.
The anticipated rise in cancer prevalence is set to drive the growth of the tyrosine kinase inhibitors market in the future. Cancer, a diverse group of diseases characterized by uncontrolled cell growth, poses a significant health challenge as abnormal cells proliferate, invade neighboring tissues, and potentially spread to other organs. Tyrosine kinase inhibitors play a crucial role in targeted therapy by blocking specific tyrosine kinases, thereby inhibiting the growth of cancer cells. As of January 2023, the American Cancer Society reported an increase in cancer cases from 1,898,160 in 2021 to 1,958,310 in 2023, representing a growth of 3.16%. This surge in cancer cases is a key driver fueling the growth of the tyrosine kinase inhibitors market.
The growth of the tyrosine kinase inhibitors market is being driven by an increase in healthcare spending. Healthcare spending refers to the total financial resources allocated to the healthcare sector within a specific region, country, or organization. This spending supports the development and use of tyrosine kinase inhibitors, which are targeted therapies for specific cancer types and other conditions. For example, in September 2024, statistics published by Cross River Therapy, a US-based provider of ABA therapy services, revealed that the U.S. pharmaceutical industry generated $550 billion in revenue. In 2021, Americans spent $576.9 billion on medicine, and projected spending is expected to rise to between $605 and $635 billion by 2025. Therefore, the increase in healthcare spending is propelling the growth of the tyrosine kinase inhibitors market moving forward.
Product innovations are becoming a significant trend in the tyrosine kinase inhibitor market. Major companies in this sector are adopting new technologies to maintain their competitive edge. For example, in February 2023, Xspray Pharma AB, a Swedish pharmaceutical firm, entered into an agreement with EVERSANA, a US-based life sciences service provider, to support the U.S. launch and commercialization of its first innovative cancer therapy, Dasynoc. This therapy is aimed at treating chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL). Dasynoc introduces a new and unique treatment option for CML and ALL patients within the $3.5 billion U.S. tyrosine kinase inhibitor market. It marks a significant advancement for CML patients; retrospective registry data presented at ASH 2022 indicated a 5-year overall survival rate of 79% for those treated with both a tyrosine kinase inhibitor (TKI) and a proton pump inhibitor (PPI) like omeprazole, compared to 94% for patients receiving TKI alone.
Major companies in the neoantigens targeted therapies market are strategically forming partnerships to establish robust and comprehensive intellectual property. Strategic partnerships involve leveraging each other's strengths and resources for mutual benefits and success. In March 2023, Mithra Pharmaceuticals SA, a Belgian-based biotechnology company, entered into a partnership with BCI Pharma, a France-based pharmaceutical technology company. The collaboration aims to develop novel tyrosine kinase inhibitors, focusing primarily on endometriosis and cancer, including orphan indications such as triple-negative breast cancer (TNBC).
In June 2022, Bristol Myers Squibb, a US-based pharmaceutical company, completed the acquisition of Turning Point Therapeutics Inc. for an undisclosed amount. This strategic move enables Bristol Myers Squibb to expand its leading oncology franchise and fully harness the potential of the precision oncology platform for enhancing standard cancer treatment. Turning Point Therapeutics Inc., a US-based pharmaceutical company, specializes in manufacturing precision medicines for cancer and other diseases, including tyrosine kinase inhibitors.
Major companies operating in the tyrosine kinase inhibitors market include Pfizer Inc., Johnson And Johnson Private Limited., F. Hoffmann-La Roche AG, AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca Plc., GlaxoSmithKline plc, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Eisai Co. Ltd, Incyte Corporation, Dr. Reddy's Laboratories Ltd., Exelixis Inc., Glenmark Pharmaceuticals Ltd, Blueprint Medicines Corporation, Rigel Pharmaceuticals Inc., Deciphera Pharmaceuticals LLC, Epizyme Inc., Turning Point Therapeutics Inc., Kura Oncology Inc., ArQule Inc.
North America was the largest region in the tyrosine kinase inhibitors market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the tyrosine kinase inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the tyrosine kinase inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tyrosine kinase inhibitors (TKI) constitute a class of pharmaceuticals designed to impede multiple pathways through which protein kinases signal the transduction pathway's function. This targeted therapy is employed to selectively target and eliminate specific cancer cell types while preserving healthy cells.
The primary categories of tyrosine kinase inhibitors include BCR-ABL tyrosine kinase inhibitors, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors, and others. BCR-ABL tyrosine kinase inhibitors specifically target the enzyme inhibiting BCR-ABL tyrosine kinases, crucial in the pathogenesis of chronic myelogenous leukemia (CML), serving as a first-line therapy for patients with CML. These inhibitors are distributed through various channels such as hospital pharmacies, independent pharmacies, and online pharmacies, and are applied in the treatment of conditions such as chronic myeloid leukemia (CML), lung cancer, breast cancer, renal cell cancer, and others.
The tyrosine kinase inhibitors market research report is one of a series of new reports that provides tyrosine kinase inhibitors market statistics, including tyrosine kinase inhibitors industry global market size, regional shares, competitors with a tyrosine kinase inhibitors market share, detailed tyrosine kinase inhibitors market segments, market trends and opportunities, and any further data you may need to thrive in the tyrosine kinase inhibitors industry. This tyrosine kinase inhibitors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The tyrosine kinase inhibitors market consists of sales of gleevec, dasatinib (Sprycel), nilotinib (Tasigna), erlotinib (Tarceva), crizotinib (Xalkori), and sunitinib (Sutent). Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The tyrosine kinase inhibitors market size is expected to see strong growth in the next few years. It will grow to $88.74 billion in 2029 at a compound annual growth rate (CAGR) of 8.8%. The growth in the forecast period can be attributed to growing healthcare investments, biomarker-driven therapies, drug delivery innovations, precision medicine paradigm, pediatric oncology focus. Major trends in the forecast period include resistance mitigation strategies, development of CNS-penetrant tkis, non-oncology applications, liquid biopsies for monitoring, health economic considerations.
The anticipated rise in cancer prevalence is set to drive the growth of the tyrosine kinase inhibitors market in the future. Cancer, a diverse group of diseases characterized by uncontrolled cell growth, poses a significant health challenge as abnormal cells proliferate, invade neighboring tissues, and potentially spread to other organs. Tyrosine kinase inhibitors play a crucial role in targeted therapy by blocking specific tyrosine kinases, thereby inhibiting the growth of cancer cells. As of January 2023, the American Cancer Society reported an increase in cancer cases from 1,898,160 in 2021 to 1,958,310 in 2023, representing a growth of 3.16%. This surge in cancer cases is a key driver fueling the growth of the tyrosine kinase inhibitors market.
The growth of the tyrosine kinase inhibitors market is being driven by an increase in healthcare spending. Healthcare spending refers to the total financial resources allocated to the healthcare sector within a specific region, country, or organization. This spending supports the development and use of tyrosine kinase inhibitors, which are targeted therapies for specific cancer types and other conditions. For example, in September 2024, statistics published by Cross River Therapy, a US-based provider of ABA therapy services, revealed that the U.S. pharmaceutical industry generated $550 billion in revenue. In 2021, Americans spent $576.9 billion on medicine, and projected spending is expected to rise to between $605 and $635 billion by 2025. Therefore, the increase in healthcare spending is propelling the growth of the tyrosine kinase inhibitors market moving forward.
Product innovations are becoming a significant trend in the tyrosine kinase inhibitor market. Major companies in this sector are adopting new technologies to maintain their competitive edge. For example, in February 2023, Xspray Pharma AB, a Swedish pharmaceutical firm, entered into an agreement with EVERSANA, a US-based life sciences service provider, to support the U.S. launch and commercialization of its first innovative cancer therapy, Dasynoc. This therapy is aimed at treating chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL). Dasynoc introduces a new and unique treatment option for CML and ALL patients within the $3.5 billion U.S. tyrosine kinase inhibitor market. It marks a significant advancement for CML patients; retrospective registry data presented at ASH 2022 indicated a 5-year overall survival rate of 79% for those treated with both a tyrosine kinase inhibitor (TKI) and a proton pump inhibitor (PPI) like omeprazole, compared to 94% for patients receiving TKI alone.
Major companies in the neoantigens targeted therapies market are strategically forming partnerships to establish robust and comprehensive intellectual property. Strategic partnerships involve leveraging each other's strengths and resources for mutual benefits and success. In March 2023, Mithra Pharmaceuticals SA, a Belgian-based biotechnology company, entered into a partnership with BCI Pharma, a France-based pharmaceutical technology company. The collaboration aims to develop novel tyrosine kinase inhibitors, focusing primarily on endometriosis and cancer, including orphan indications such as triple-negative breast cancer (TNBC).
In June 2022, Bristol Myers Squibb, a US-based pharmaceutical company, completed the acquisition of Turning Point Therapeutics Inc. for an undisclosed amount. This strategic move enables Bristol Myers Squibb to expand its leading oncology franchise and fully harness the potential of the precision oncology platform for enhancing standard cancer treatment. Turning Point Therapeutics Inc., a US-based pharmaceutical company, specializes in manufacturing precision medicines for cancer and other diseases, including tyrosine kinase inhibitors.
Major companies operating in the tyrosine kinase inhibitors market include Pfizer Inc., Johnson And Johnson Private Limited., F. Hoffmann-La Roche AG, AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca Plc., GlaxoSmithKline plc, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Eisai Co. Ltd, Incyte Corporation, Dr. Reddy's Laboratories Ltd., Exelixis Inc., Glenmark Pharmaceuticals Ltd, Blueprint Medicines Corporation, Rigel Pharmaceuticals Inc., Deciphera Pharmaceuticals LLC, Epizyme Inc., Turning Point Therapeutics Inc., Kura Oncology Inc., ArQule Inc.
North America was the largest region in the tyrosine kinase inhibitors market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the tyrosine kinase inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the tyrosine kinase inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tyrosine kinase inhibitors (TKI) constitute a class of pharmaceuticals designed to impede multiple pathways through which protein kinases signal the transduction pathway's function. This targeted therapy is employed to selectively target and eliminate specific cancer cell types while preserving healthy cells.
The primary categories of tyrosine kinase inhibitors include BCR-ABL tyrosine kinase inhibitors, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors, and others. BCR-ABL tyrosine kinase inhibitors specifically target the enzyme inhibiting BCR-ABL tyrosine kinases, crucial in the pathogenesis of chronic myelogenous leukemia (CML), serving as a first-line therapy for patients with CML. These inhibitors are distributed through various channels such as hospital pharmacies, independent pharmacies, and online pharmacies, and are applied in the treatment of conditions such as chronic myeloid leukemia (CML), lung cancer, breast cancer, renal cell cancer, and others.
The tyrosine kinase inhibitors market research report is one of a series of new reports that provides tyrosine kinase inhibitors market statistics, including tyrosine kinase inhibitors industry global market size, regional shares, competitors with a tyrosine kinase inhibitors market share, detailed tyrosine kinase inhibitors market segments, market trends and opportunities, and any further data you may need to thrive in the tyrosine kinase inhibitors industry. This tyrosine kinase inhibitors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The tyrosine kinase inhibitors market consists of sales of gleevec, dasatinib (Sprycel), nilotinib (Tasigna), erlotinib (Tarceva), crizotinib (Xalkori), and sunitinib (Sutent). Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Tyrosine Kinase Inhibitors Market Characteristics3. Tyrosine Kinase Inhibitors Market Trends and Strategies4. Tyrosine Kinase Inhibitors Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid and Recovery on the Market32. Global Tyrosine Kinase Inhibitors Market Competitive Benchmarking and Dashboard33. Key Mergers and Acquisitions in the Tyrosine Kinase Inhibitors Market34. Recent Developments in the Tyrosine Kinase Inhibitors Market
5. Global Tyrosine Kinase Inhibitors Growth Analysis and Strategic Analysis Framework
6. Tyrosine Kinase Inhibitors Market Segmentation
7. Tyrosine Kinase Inhibitors Market Regional and Country Analysis
8. Asia-Pacific Tyrosine Kinase Inhibitors Market
9. China Tyrosine Kinase Inhibitors Market
10. India Tyrosine Kinase Inhibitors Market
11. Japan Tyrosine Kinase Inhibitors Market
12. Australia Tyrosine Kinase Inhibitors Market
13. Indonesia Tyrosine Kinase Inhibitors Market
14. South Korea Tyrosine Kinase Inhibitors Market
15. Western Europe Tyrosine Kinase Inhibitors Market
16. UK Tyrosine Kinase Inhibitors Market
17. Germany Tyrosine Kinase Inhibitors Market
18. France Tyrosine Kinase Inhibitors Market
19. Italy Tyrosine Kinase Inhibitors Market
20. Spain Tyrosine Kinase Inhibitors Market
21. Eastern Europe Tyrosine Kinase Inhibitors Market
22. Russia Tyrosine Kinase Inhibitors Market
23. North America Tyrosine Kinase Inhibitors Market
24. USA Tyrosine Kinase Inhibitors Market
25. Canada Tyrosine Kinase Inhibitors Market
26. South America Tyrosine Kinase Inhibitors Market
27. Brazil Tyrosine Kinase Inhibitors Market
28. Middle East Tyrosine Kinase Inhibitors Market
29. Africa Tyrosine Kinase Inhibitors Market
30. Tyrosine Kinase Inhibitors Market Competitive Landscape and Company Profiles
31. Tyrosine Kinase Inhibitors Market Other Major and Innovative Companies
35. Tyrosine Kinase Inhibitors Market High Potential Countries, Segments and Strategies
36. Appendix
Executive Summary
Tyrosine Kinase Inhibitors Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on tyrosine kinase inhibitors market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for tyrosine kinase inhibitors? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The tyrosine kinase inhibitors market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Type: BCR-ABL Tyrosine Kinase Inhibitor; Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors; Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitors; Other Types2) By Distribution Channel: Hospital Pharmacy; Independent Pharmacies; Online Pharmacies
3) By Application: Chronic Myeloid Leukemia (CML); Lung Cancer; Breast Cancer; Renal Cell Cancer; Other Applications
Subsegments:
1) By BCR-ABL Tyrosine Kinase Inhibitor: Imatinib; Dasatinib; Nilotinib; Bosutinib; Ponatinib2) By Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors: Gefitinib; Erlotinib; Afatinib; Osimertinib; Dacomitinib
3) By Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitors: Sorafenib; Sunitinib; Pazopanib; Axitinib; Regorafenib
4) By Other Types: Platelet-Derived Growth Factor Receptor (PDGFR) Inhibitors; RET Tyrosine Kinase Inhibitors; Fibroblast Growth Factor Receptor (FGFR) Inhibitors; Other Emerging Tyrosine Kinase Inhibitors
Key Companies Mentioned: Pfizer Inc.; Johnson and Johnson Private Limited.; F. Hoffmann-La Roche AG; AbbVie Inc.; Bayer AG
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- Pfizer Inc.
- Johnson And Johnson Private Limited.
- F. Hoffmann-La Roche AG
- AbbVie Inc.
- Bayer AG
- Novartis AG
- Sanofi S.A.
- Bristol-Myers Squibb Company
- AstraZeneca Plc.
- GlaxoSmithKline plc
- Eli Lilly and Company
- Amgen Inc.
- Boehringer Ingelheim International GmbH
- Teva Pharmaceutical Industries Ltd.
- Regeneron Pharmaceuticals Inc.
- Astellas Pharma Inc.
- Eisai Co. Ltd
- Incyte Corporation
- Dr. Reddy's Laboratories Ltd.
- Exelixis Inc.
- Glenmark Pharmaceuticals Ltd
- Blueprint Medicines Corporation
- Rigel Pharmaceuticals Inc.
- Deciphera Pharmaceuticals LLC
- Epizyme Inc.
- Turning Point Therapeutics Inc.
- Kura Oncology Inc.
- ArQule Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | February 2025 |
| Forecast Period | 2025 - 2029 |
| Estimated Market Value ( USD | $ 63.25 Billion |
| Forecasted Market Value ( USD | $ 88.74 Billion |
| Compound Annual Growth Rate | 8.8% |
| Regions Covered | Global |
| No. of Companies Mentioned | 28 |
